Risk adjusted net present value: What is the current valuation of TScan Therapeutics’s TSC-200-A0201?
TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of TSC-200-A0201’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.The revenue for TSC-200-A0201 is expected to reach an annual total of $13 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.TSC-200-A0201 OverviewTSC-200 is under development for the treatment of HPV-positive cancers including head & neck, cervical, NSCLC and metastatic ovarian cancer, and metastatic melanoma and anal cancers. The therapeutic candidate comprises of T cells engineered to express a TCR of interest which are mixed with a genome-wide library of target cell. The drug candidate is developed based on the TScan platform technology. It acts by targeting HPV16.TScan Therapeutics OverviewTScan Therapeutics (TCR) provides life-changing T cell therapies for patients. It is headquartered in Boston, Massachusetts, the US. The company reported revenues of (US Dollars) US$13.5 million for the fiscal year ended December 2022 (FY2022), an increase of 33.5% over FY2021. The operating loss of the company was US$66.6 million in FY2022, compared to an operating loss of US$48.6 million in FY2021. The net loss of the company was US$66.2 million in FY2022, compared to a net loss of US$48.6 million in FY2021. The company reported revenues of US$6.8 million for the first quarter ended March 2023, compared to a revenue of US$3.1 million the previous quarter. For a complete picture of TSC-200-A0201’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.
What's Your Reaction?
